Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-022 + pembrolizumab ± chemotherapy in CLDN18.2-positive HER2-negative unresectable or metastatic gastric/GEJ cancer
CTR20254878Phase 2Active
- Sponsor
- Antengene
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ATG-022 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Antengene. Started Mar 2026; status: active.
02
Drugs
ATG-022
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20254878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254878.